Biofrontera AG has formed a wholly-owned US subsidiary, Biofrontera Inc., registered in Wilmington, Delaware. This company is intended to lay the ground for marketing and sales activities upon the expected FDA approval for the products Ameluz and BF-RhodoLED in 2016.

Monica Tamborini has been appointed CEO of Biofrontera's US operations. Monica has over 20 years experience managing US companies in the healthcare sector. Monica worked in various sectors before joining the pharmaceutical industry. Since then, Monica has held various positions as CFO and COO. In addition to her expertise in finance Monica has, as Managing Director of Calix Consulting.